5G64
 
 | | The complex between human IgE-Fc and two anti-IgE Fab fragments | | Descriptor: | FAB FRAGMENT, IG EPSILON CHAIN C REGION, alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose | | Authors: | Davies, A.M, Allan, E.G, Keeble, A.H, Delgado, J, Cossins, B.P, Mitropoulou, A.N, Pang, M.O.Y, Ceska, T, Beavil, A.J, Craggs, G, Westwood, M, Henry, A.J, McDonnell, J.M, Sutton, B.J. | | Deposit date: | 2016-06-14 | | Release date: | 2017-05-03 | | Last modified: | 2024-01-10 | | Method: | X-RAY DIFFRACTION (3.715 Å) | | Cite: | Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab.
J. Biol. Chem., 292, 2017
|
|
1O0V
 | | The crystal structure of IgE Fc reveals an asymmetrically bent conformation | | Descriptor: | GLYCEROL, Immunoglobulin heavy chain epsilon-1, SULFATE ION, ... | | Authors: | Wan, T, Beavil, R.L, Fabiane, S.M, Beavil, A.J, Sohi, M.K, Keown, M, Young, R.J, Henry, A.J, Owens, R.J, Gould, H.J, Sutton, B.J. | | Deposit date: | 2002-09-06 | | Release date: | 2002-09-18 | | Last modified: | 2023-12-27 | | Method: | X-RAY DIFFRACTION (2.6 Å) | | Cite: | The crystal structure of IgE Fc reveals an asymmetrically bent conformation
NAT.IMMUNOL., 3, 2002
|
|
1G84
 | | THE SOLUTION STRUCTURE OF THE C EPSILON2 DOMAIN FROM IGE | | Descriptor: | IMMUNOGLOBULIN E | | Authors: | McDonnell, J.M, Cowburn, D, Gould, H.J, Sutton, B.J, Calvert, R, Beavil, R.E, Beavil, A.J, Henry, A.J. | | Deposit date: | 2000-11-16 | | Release date: | 2001-05-16 | | Last modified: | 2021-10-27 | | Method: | SOLUTION NMR | | Cite: | The structure of the IgE Cepsilon2 domain and its role in stabilizing the complex with its high-affinity receptor FcepsilonRIalpha.
Nat.Struct.Biol., 8, 2001
|
|
2M2D
 | | Human programmed cell death 1 receptor | | Descriptor: | Programmed cell death protein 1 | | Authors: | Veverka, V, Cheng, X, Waters, L.C, Muskett, F.W, Morgan, S, Lesley, A, Griffiths, M, Stubberfield, C, Griffin, R, Henry, A.J, Robinson, M.K, Jansson, A, Ladbury, J.E, Ikemizu, S, Davis, S.J, Carr, M.D. | | Deposit date: | 2012-12-18 | | Release date: | 2013-02-27 | | Last modified: | 2013-05-15 | | Method: | SOLUTION NMR | | Cite: | Structure and interactions of the human programmed cell death 1 receptor.
J.Biol.Chem., 288, 2013
|
|
6TCN
 | | Crystal structure of the omalizumab Fab - crystal form II | | Descriptor: | 1,2-ETHANEDIOL, 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL, DI(HYDROXYETHYL)ETHER, ... | | Authors: | Mitropoulou, A.N, Ceska, T, Beavil, A.J, Henry, A.J, McDonnell, J.M, Sutton, B.J, Davies, A.M. | | Deposit date: | 2019-11-06 | | Release date: | 2020-03-18 | | Last modified: | 2024-01-24 | | Method: | X-RAY DIFFRACTION (2.3 Å) | | Cite: | Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization.
Acta Crystallogr.,Sect.F, 76, 2020
|
|
6TCP
 | | Crystal structure of the omalizumab Fab Leu158Pro light chain mutant - crystal form II | | Descriptor: | DI(HYDROXYETHYL)ETHER, GLYCEROL, Omalizumab Fab Leu158Pro light chain mutant, ... | | Authors: | Mitropoulou, A.N, Ceska, T, Beavil, A.J, Henry, A.J, McDonnell, J.M, Sutton, B.J, Davies, A.M. | | Deposit date: | 2019-11-06 | | Release date: | 2020-03-18 | | Last modified: | 2024-01-24 | | Method: | X-RAY DIFFRACTION (2.5 Å) | | Cite: | Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization.
Acta Crystallogr.,Sect.F, 76, 2020
|
|
6TCR
 | | Crystal structure of the omalizumab Fab Ser81Arg, Gln83Arg and Leu158Pro light chain mutant | | Descriptor: | 1,2-ETHANEDIOL, DI(HYDROXYETHYL)ETHER, Omalizumab Fab Ser81Arg, ... | | Authors: | Mitropoulou, A.N, Ceska, T, Beavil, A.J, Henry, A.J, McDonnell, J.M, Sutton, B.J, Davies, A.M. | | Deposit date: | 2019-11-06 | | Release date: | 2020-03-18 | | Last modified: | 2024-01-24 | | Method: | X-RAY DIFFRACTION (1.45 Å) | | Cite: | Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization.
Acta Crystallogr.,Sect.F, 76, 2020
|
|
6TCO
 | | Crystal structure of the omalizumab Fab Leu158Pro light chain mutant - crystal form I | | Descriptor: | 1,2-ETHANEDIOL, Omalizumab Fab Leu158Pro light chain mutant, SULFATE ION | | Authors: | Mitropoulou, A.N, Ceska, T, Beavil, A.J, Henry, A.J, McDonnell, J.M, Sutton, B.J, Davies, A.M. | | Deposit date: | 2019-11-06 | | Release date: | 2020-03-18 | | Last modified: | 2024-01-24 | | Method: | X-RAY DIFFRACTION (1.8 Å) | | Cite: | Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization.
Acta Crystallogr.,Sect.F, 76, 2020
|
|
6TCM
 | | Crystal structure of the omalizumab Fab - crystal form I | | Descriptor: | (4S)-2-METHYL-2,4-PENTANEDIOL, GLYCEROL, Omalizumab Fab, ... | | Authors: | Mitropoulou, A.N, Ceska, T, Beavil, A.J, Henry, A.J, McDonnell, J.M, Sutton, B.J, Davies, A.M. | | Deposit date: | 2019-11-06 | | Release date: | 2020-03-18 | | Last modified: | 2024-01-24 | | Method: | X-RAY DIFFRACTION (1.85 Å) | | Cite: | Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization.
Acta Crystallogr.,Sect.F, 76, 2020
|
|
6TCS
 | | Crystal structure of the omalizumab scFv | | Descriptor: | DI(HYDROXYETHYL)ETHER, Omalizumab scFv | | Authors: | Mitropoulou, A.N, Ceska, T, Beavil, A.J, Henry, A.J, McDonnell, J.M, Sutton, B.J, Davies, A.M. | | Deposit date: | 2019-11-06 | | Release date: | 2020-03-18 | | Last modified: | 2024-01-24 | | Method: | X-RAY DIFFRACTION (2.3 Å) | | Cite: | Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization.
Acta Crystallogr.,Sect.F, 76, 2020
|
|
6TCQ
 | | Crystal structure of the omalizumab Fab Ser81Arg and Gln83Arg light chain mutant | | Descriptor: | GLYCEROL, Omalizumab Fab Ser81Arg and Gln83Arg light chain mutant | | Authors: | Mitropoulou, A.N, Ceska, T, Beavil, A.J, Henry, A.J, McDonnell, J.M, Sutton, B.J, Davies, A.M. | | Deposit date: | 2019-11-06 | | Release date: | 2020-03-18 | | Last modified: | 2024-01-24 | | Method: | X-RAY DIFFRACTION (2.05 Å) | | Cite: | Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization.
Acta Crystallogr.,Sect.F, 76, 2020
|
|
2KH2
 | | Solution structure of a scFv-IL-1B complex | | Descriptor: | Interleukin-1 beta, scFv | | Authors: | Wilkinson, I.C, Hall, C.J, Veverka, V, Muskett, F.W, Stephens, P.E, Taylor, R.J, Henry, A.J, Carr, M.D. | | Deposit date: | 2009-03-23 | | Release date: | 2009-09-08 | | Last modified: | 2022-03-16 | | Method: | SOLUTION NMR | | Cite: | High resolution NMR-based model for the structure of a scFv-IL-1beta complex: potential for NMR as a key tool in therapeutic antibody design and development.
J.Biol.Chem., 284, 2009
|
|
2K8P
 | | Characterisation of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation | | Descriptor: | Sclerostin | | Authors: | Veverka, V, Henry, A.J, Slocombe, P.M, Ventom, A, Mulloy, B, Muskett, F.W, Muzylak, M, Greenslade, K, Moore, A, Zhang, L, Gong, J, Qian, X, Paszty, C, Taylor, R.J, Robinson, M.K, Carr, M.D. | | Deposit date: | 2008-09-18 | | Release date: | 2009-02-17 | | Last modified: | 2022-03-16 | | Method: | SOLUTION NMR | | Cite: | Characterization of the Structural Features and Interactions of Sclerostin: Molecular insight into a key regulator of Wnt-mediated bone formation
J.Biol.Chem., 284, 2009
|
|
2L3Y
 | | Solution structure of mouse IL-6 | | Descriptor: | Interleukin-6 | | Authors: | Veverka, V, Redpath, N.T, Carrington, B, Muskett, F.W, Taylor, R.J, Henry, A.J, Carr, M.D. | | Deposit date: | 2010-09-25 | | Release date: | 2011-09-28 | | Last modified: | 2013-01-02 | | Method: | SOLUTION NMR | | Cite: | Conservation of functional sites on interleukin-6 and implications for evolution of signaling complex assembly and therapeutic intervention.
J.Biol.Chem., 287, 2012
|
|
2KZT
 | | Structure of the Tandem MA-3 Region of Pdcd4 | | Descriptor: | Programmed cell death protein 4 | | Authors: | Waters, L.C, Strong, S.L, Oka, O, Muskett, F.W, Veverka, V, Banerjee, S, Schmedt, T, Henry, A.J, Klempnauer, K.H, Carr, M.D. | | Deposit date: | 2010-06-24 | | Release date: | 2011-03-16 | | Last modified: | 2011-11-23 | | Method: | SOLUTION NMR | | Cite: | Structure of the tandem MA-3 region of Pdcd4 protein and characterization of its interactions with eIF4A and eIF4G: molecular mechanisms of a tumor suppressor
J.Biol.Chem., 286, 2011
|
|
